- Venture Funds
- Corporate Venture Capital
GV (Google Ventures)
Status
ACTIVE
Global HQ
Mountain View, United States
Countries of investment
- United States
- United Kingdom
- Israel
- Germany
- France
- Canada
Investment stages
- Seed
- Series A
- Series B
- Series C
- Growth
Industries
- AI
- Generative AI
- Enterprise Software
- Cybersecurity
- Life Sciences
- Biotechnology
- Digital Health
- Health Tech
- Cloud Computing
- Software
About
GV, launched in 2009 as Google Ventures, is the venture capital arm of Alphabet, its sole limited partner, and manages over $13B in assets. It invests from seed to growth in technology and life sciences and has around 400 active portfolio companies across North America, Europe and Israel. GV has backed more than 50 AI application companies and 20 AI healthcare companies, including Vercel, Harvey, Synthesia, Isomorphic Labs and insitro. It is headquartered in the San Francisco Bay Area with offices in New York, Cambridge and London.
GV, launched in 2009 as Google Ventures, is the venture capital arm of Alphabet, its sole limited partner, and manages over $13B in assets. It invests from seed to growth in technology and life sciences and has around 400 active portfolio companies across North America, Europe and Israel. GV has backed more than 50 AI application companies and 20 AI healthcare companies, including Vercel, Harvey, Synthesia, Isomorphic Labs and insitro. It is headquartered in the San Francisco Bay Area with offices in New York, Cambridge and London.
Investment Thesis
GV is Alphabet's venture arm, investing from seed to growth in technology and life sciences across North America, Europe and Israel. It backs AI applications, developer tools, security, infrastructure and AI-driven healthcare and drug discovery. Its differentiation is a single deep-pocketed LP in Alphabet, financial independence in decisions and access to Google expertise and engineering partners.
Manager's Experience
Managing Partners Dave Munichiello, Krishna Yeshwant and Tom Hulme lead GV's technology, life sciences and European investing respectively. Krishna Yeshwant, a physician, has led many of GV's healthcare investments, while Tom Hulme built the London team behind deals such as Synthesia. The firm has grown to over $13B in assets and about 400 active portfolio companies since 2009.
Team
Dave Munichiello - Managing Partner
Krishna Yeshwant - Managing Partner
Tom Hulme - Managing Partner
Karim Faris - General Partner
Crystal Huang - General Partner
Frederique Dame - General Partner
David Schenkein - General Partner
Issi Rozen - General Partner
Portfolio
Vercel
Harvey
Synthesia
Isomorphic Labs
insitro
Hebbia
Lightmatter
SambaNova
Snorkel
StackBlitz